Cassava Sciences, Inc.
General ticker "SAVA" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $749.4M (TTM average)
Cassava Sciences, Inc. follows the US Stock Market performance with the rate: 42.7%.
Estimated limits based on current volatility of 4.9%: low 2.99$, high 3.30$
Factors to consider:
- Total employees count: 30 (+3.4%) as of 2024
- Top business risk factors: Clinical trial failures, Regulatory and compliance, Supply chain disruptions, Operational and conduct risks, Patent risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.52$, 4.08$]
- 2025-12-31 to 2026-12-31 estimated range: [1.27$, 3.52$]
Financial Metrics affecting the SAVA estimates:
- Positive: with PPE of -0.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -104.92 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 92.49 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.09 > -0.66
Short-term SAVA quotes
Long-term SAVA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $80.02MM | $105.96MM | $141.45MM |
| Operating Income | $-80.02MM | $-105.96MM | $-141.45MM |
| Non-Operating Income | $3.77MM | $8.74MM | $117.10MM |
| R&D Expense | $68.03MM | $89.42MM | $69.64MM |
| Income(Loss) | $-76.25MM | $-97.22MM | $-24.34MM |
| Profit(Loss)* | $-76.25MM | $-97.22MM | $-24.34MM |
| Stockholders Equity | $227.54MM | $137.47MM | $145.70MM |
| Assets | $234.83MM | $151.66MM | $157.53MM |
| Operating Cash Flow | $-77.51MM | $-82.03MM | $-116.93MM |
| Capital expenditure | $2.71MM | $0.41MM | $0.10MM |
| Investing Cash Flow | $-2.71MM | $-0.41MM | $-0.10MM |
| Financing Cash Flow | $47.80MM | $2.56MM | $124.47MM |
| Earnings Per Share** | $-1.90 | $-2.32 | $-0.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.